Figure 7. Myeloid cell activation through TLR independent agents results in survival benefit in a mouse glioma model.

Administration of CSF1R (A) and STING (B) with anti-PD-1 results in an enhanced survival benefit in a mouse model of glioma. Administration of FLT3L (C) with anti-PD-1 does not increase survival compared to monotherapy. All groups in CSF1F and FLT3L had 10 mice per arm, studies were repeated at least once. STING survival study had 40 mice per group.